Nanologica AB Total Assets
Nanologica AB total assets. Based on the latest financial reports, Nanologica AB (NICA) holds total assets worth Skr262.32 Million SEK (≈ $28.23 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Nanologica AB for the company's overall valuation and market capitalisation.
Total Assets of Nanologica AB (2012–2025)
Total assets of Nanologica AB from 2012 to 2025. This chart illustrates how Nanologica AB's total assets have evolved over time, based on quarterly financial data. See Nanologica AB (NICA) share price today for real-time trading data and today's change.
Nanologica AB - Asset Composition Analysis
Nanologica AB Total Assets Breakdown (December 2025)
Nanologica AB total assets breakdown as of December 2025. Nanologica AB's total assets of Skr262.32 Million consist of 76.8% current assets and 23.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 4.0% |
| Accounts Receivable | Skr4.69 Million | 5.3% |
| Inventory | Skr27.72 Million | 31.5% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr9.46 Million | 10.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Nanologica AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NICA current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanologica AB's current assets represent 76.8% of total assets in 2025, an increase from 15.8% in 2012.
- Cash Position: Cash and equivalents constituted 4.0% of total assets in 2025, down from 7.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 12.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 31.5% of total assets.
Nanologica AB Competitors by Total Assets
Key competitors of Nanologica AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Nanologica AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 5.43 | 4.88 |
| Quick Ratio | 0.80 | 3.86 | 4.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr17.95 Million | Skr80.85 Million | Skr67.29 Million |
Nanologica AB - Advanced Valuation Insights
This section examines the relationship between Nanologica AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -38.4% |
| Total Assets | Skr88.11 Million |
| Market Capitalization | $5.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanologica AB's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Nanologica AB's assets decreased by 38.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nanologica AB (2012–2025)
The table below shows the annual total assets of Nanologica AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr88.11 Million ≈ $9.48 Million |
-38.43% |
| 2024-12-31 | Skr143.10 Million ≈ $15.40 Million |
+84.81% |
| 2023-12-31 | Skr77.43 Million ≈ $8.33 Million |
-49.89% |
| 2022-12-31 | Skr154.51 Million ≈ $16.63 Million |
+57.16% |
| 2021-12-31 | Skr98.32 Million ≈ $10.58 Million |
-32.82% |
| 2020-12-31 | Skr146.34 Million ≈ $15.75 Million |
+246.08% |
| 2019-12-31 | Skr42.29 Million ≈ $4.55 Million |
+23.18% |
| 2018-12-31 | Skr34.33 Million ≈ $3.69 Million |
+32.48% |
| 2017-12-31 | Skr25.91 Million ≈ $2.79 Million |
-18.69% |
| 2016-12-31 | Skr31.87 Million ≈ $3.43 Million |
-2.74% |
| 2015-12-31 | Skr32.77 Million ≈ $3.53 Million |
+67.22% |
| 2014-12-31 | Skr19.60 Million ≈ $2.11 Million |
+40.98% |
| 2013-12-31 | Skr13.90 Million ≈ $1.50 Million |
+114.36% |
| 2012-12-31 | Skr6.48 Million ≈ $697.79K |
-- |
About Nanologica AB
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange prod… Read more